Myklebost O - Search Results

1

Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.

Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O. Ohnstad HO, et al. Among authors: myklebost o. Cancer. 2013 Mar 1;119(5):1013-22. doi: 10.1002/cncr.27837. Epub 2012 Nov 16. Cancer. 2013. PMID: 23165797 Free article.

2

Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression.

Flørenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O. Flørenes VA, et al. Among authors: myklebost o. Cancer Res. 1992 Nov 1;52(21):6088-91. Cancer Res. 1992. PMID: 1356624

3

Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas--relationship to amplification and mRNA levels of CDK4 and CCND1.

Maelandsmo GM, Berner JM, Flørenes VA, Forus A, Hovig E, Fodstad O, Myklebost O. Maelandsmo GM, et al. Among authors: myklebost o. Br J Cancer. 1995 Aug;72(2):393-8. doi: 10.1038/bjc.1995.344. Br J Cancer. 1995. PMID: 7640224 Free PMC article.

4

The protooncogene CHOP/GADD153, involved in growth arrest and DNA damage response, is amplified in a subset of human sarcomas.

Forus A, Flørenes VA, Maelandsmo GM, Fodstad O, Myklebost O. Forus A, et al. Among authors: myklebost o. Cancer Genet Cytogenet. 1994 Dec;78(2):165-71. doi: 10.1016/0165-4608(94)90085-x. Cancer Genet Cytogenet. 1994. PMID: 7828148

5

MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.

Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. Flørenes VA, et al. Among authors: myklebost o. J Natl Cancer Inst. 1994 Sep 7;86(17):1297-302. doi: 10.1093/jnci/86.17.1297. J Natl Cancer Inst. 1994. PMID: 8064888

6

Mapping of amplification units in the q13-14 region of chromosome 12 in human sarcomas: some amplica do not include MDM2.

Forus A, Flørenes VA, Maelandsmo GM, Meltzer PS, Fodstad O, Myklebost O. Forus A, et al. Among authors: myklebost o. Cell Growth Differ. 1993 Dec;4(12):1065-70. Cell Growth Differ. 1993. PMID: 8117620

7

p53 abnormalities in different subtypes of human sarcomas.

Andreassen A, Oyjord T, Hovig E, Holm R, Flørenes VA, Nesland JM, Myklebost O, Høie J, Bruland OS, Børresen AL, et al. Andreassen A, et al. Among authors: myklebost o. Cancer Res. 1993 Feb 1;53(3):468-71. Cancer Res. 1993. PMID: 8425179

8

Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas.

Berner JM, Forus A, Elkahloun A, Meltzer PS, Fodstad O, Myklebost O. Berner JM, et al. Among authors: myklebost o. Genes Chromosomes Cancer. 1996 Dec;17(4):254-9. doi: 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2. Genes Chromosomes Cancer. 1996. PMID: 8946207

9

Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme.

Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Flørenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad O. Maelandsmo GM, et al. Among authors: myklebost o. Cancer Res. 1996 Dec 1;56(23):5490-8. Cancer Res. 1996. PMID: 8968106

10

HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas.

Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O. Berner JM, et al. Among authors: myklebost o. Oncogene. 1997 Jun 19;14(24):2935-41. doi: 10.1038/sj.onc.1201135. Oncogene. 1997. PMID: 9205100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

233 results

Search Page